These findings provide new insights into the distinct neurocircuit changes associated with the antipsychotic-like effects of TAAR1 agonists, distinguishing them from D2 receptor-targeting treatments.
D2R signaling is identified as a major determinant of iMSN structural and intrinsic physiological integrity and global loss of D2R function reproduces many of the adaptations induced by dopamine depletion, indicating that dopamine depletion drives distinct forms of plasticity through separable D2R dependent and indepen...
Samuel Alberquilla, Carlos Salas Prieto, Paula Merino Serrais et al.· Neurobiology of Disease· 0 citations
Abstract Background Current antipsychotic treatments primarily rely on dopamine D2 receptor antagonism and show limited efficacy for negative and cognitive symptoms, as well as in treatment-resistant schizophrenia. Trace amine-associated receptor 1 (TAAR1) agonists represent a promising non-dopaminergic approach with a...
G. Rutigliano· International Journal of Neu...· 0 citations
Abstract Background Trace amine associated receptor 1 (TAAR1) is a promising target for the next generation of the central nervous system (CNS) drugs. It has been previously shown that the full (RO5256390) and partial (RO5263397) agonists of TAAR1 had anti-addictive, pro-cognitive, and antipsychotic- and antidepressant...
T. Khoury, D. Grinchii, M. Hoener et al.· International Journal of Neu...· 0 citations
It is shown that D2Rs can bypass second messenger systems to tune glutamatergic transmission through receptor-receptor interactions, providing a mechanism by which dopamine selectively gates specific glutamatergic inputs to control striatal plasticity and behavioral adaptation.
Sheng Gong, J. Adler, Ying Zhu et al.· Science Advances· 0 citations